TG Therapeutics to Seek Accelerated Approval of Umbralisib for Marginal Zone Lymphoma
News
After positive feedback from the U.S. Food and Drug Administration, TG Therapeutics is planning to pursue accelerated approval for umbralisib (TGR-1202) as a treatment for patients with marginal zone lymphoma (MZL). ... Read more